Skip navigation Consumer Fund Healthcare Info & Comm Technology Internet & Digital Media

AVEO Pharmaceuticals

AVEO is a biopharmaceutical company focused on the discovery and development of drugs that target gene products critical for the maintenance and recurrence of established cancers. AVEO is positioned to revolutionize cancer drug discovery and development by employing powerful, proprietary genetic model systems to discover and develop drugs against essential targets critical to the origin, maintenance and spread of malignant tumors. This novel high-throughput in vivo technology platform enables the rapid functional identification and prioritization of only the most relevant drug targets – dramatically improving the efficiency of drug discovery. Additionally, by identifying patient populations likely to be responsive to drug therapy, AVEO’s technology enables smarter drug development, decreased development costs and improved attrition.

Recent News

Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License Agreement

AVEO Pharmaceuticals’ Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

AVEO Pharmaceuticals to Present at 26th Annual JPMorgan Healthcare Conference

AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project

AVEO Pharmaceuticals to Present at Lazard Capital Markets 4th Annual Healthcare Conference

Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers